On Tuesday, Pfizer Inc. (PFE.N) Chief Executive Officer Albert Bourla announced that the firm has submitted a request to the US Food and Drug Administration for approval of its COVID-19 booster dosages for use in 16 and 17-year-olds.
All individuals 18 and older are now eligible for a booster dosage of Pfizer and BioNTech's vaccine, which must be administered at least six months after the second injection, according to US authorities.
If approved, Pfizer's booster vaccine will be the first to be approved for use in children under the age of 18.
According to the Wall Street Journal, the FDA might approve Pfizer's booster dosages for 16- and 17-year-olds as early as next week.
The US government and health officials are pressing for more immunizations to stop the spread of the extremely contagious Omicron coronavirus strain, which was initially discovered in southern Africa.